NASDAQ : RZLT

Rezolute, Inc. — Company profile

Healthcare · Biotechnology · United States

Last price 3.95 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 414.34M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody which is in Phase 3 clinical trial to treat tumor HI indication, as well as congenital HI. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.

Details

NameRezolute, Inc.
SectorHealthcare
IndustryBiotechnology
Employees58
Founded2010
CeoNevan Elam
CountryUnited States
ExchangeNASDAQ
Fiscal YearJuly - June
Reporting CurrencyUSD
IsinUS76200L3096
Cusip76200L309
Cik0001509261
Sic2834
Stock TypeCommon Stock

Key executives

NameTitle
Nevan Charles Elam J.D.Founder, Chief Executive Officer and Acting Chairman of the Board
Daron G. Evans M.B.A., M.S.Chief Financial and Business Officer
Dr. Brian Kenneth Roberts M.D.Chief Medical Officer
Sunil Karnawat M.B.A., Ph.D.Chief Commercial Officer
Michael R. DeperroSenior Vice President and Head of Operations
Dr. Davelyn Eaves Hood M.B.A., M.D.Director and Head of Scientific and Patient Affairs
Melissa QuinnSenior Director of People and Culture
Chris MilksVice President and Head of Finance
Robyn SweinhartVice President and Head of Quality
Erin O'BoyleSenior Vice President and Head of Clinical Operations

Contact

Address275 Shoreline Drive, Suite 500, Redwood City, California 94065, United States
Phone650 206 4507
Websitehttps://www.rezolutebio.com